---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-007587"
form_type: "8-K"
ticker: "BCTX"
cik: "0001610820"
company_name: "BriaCell Therapeutics Corp."
filed_at: "2026-02-20T23:59:59+00:00"
generated_at: "2026-05-16T01:27:46.352442+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BriaCell transfers exclusive sCD80 license to BriaPro; receives 23.97M shares, increases stake to 78%

## Summary
- BriaCell transfers exclusive license for Soluble CD80 to BriaPro for 23,972,589 BriaPro shares, increasing stake to ~78%.
- BriaCell provides up to $3M credit facility to BriaPro for R&D; each drawdown subject to BriaCell approval.
- Transaction expected to close March 12, 2026, subject to disinterested shareholder approval and independent valuation.
- License originally from University of Maryland Baltimore County; sCD80 showed anti-tumor activity in animal models.
- BriaPro stock valued at approx. C$1.18M aggregate; BriaPro to pay 2% royalties to UMBC upon commercialization.

## SEC filing metadata
- accession: 0001493152-26-007587
- form_type: 8-K
- ticker: BCTX
- cik: 0001610820
- company_name: BriaCell Therapeutics Corp.
- filed_at: 2026-02-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610820/000149315226007587/0001493152-26-007587-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610820/000149315226007587/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-007587
- JSON: https://secwatch.observer/filing/0001493152-26-007587.json
- Plain text: https://secwatch.observer/filing/0001493152-26-007587.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.